v-Two variant cells lines resistant to the nitrosourea derivative ACNU (( 1-4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride), namely C6/ACNU and 9L/ACNU, were selected in vivo from rat brain tumors. Stable resistance to ACNU proved to be a characteristic of these cell lines, whether they were grown in vivo or in vitro. These cell lines exhibited a different pattern of cross-resistance to a wide range of chemotherapeutic agents with dissimilar chemical structures and mechanisms of action as compared with that of other ACNU-resistant cell lines established in vitro. Distinct cross-resistance was observed in both the C6/ACNU and 9L/ACNU cell lines to chloroethyl-nitrosoureas such as BCNU (carmustine), CCNU (lomustine), and methyl CCNU and, additionally, to vincristine, vinblastine, Adriamycin (doxorubicin), and arabinosylcytosine, but not to bleomycin, methotrexate, cis-platinum, and 5-fluorouracil. This might point to a multifactorial mechanism of drug resistance in ACNU-resistant cell lines derived from rat C6 and 9L brain tumor cells.
A
NUMBER of chemotherapeutic agents used in the treatment of malignant tumors induce complete remission in some malignancies. Even in patients harboring brain tumors, the administration of nitrosourea derivatives has improved survival time." These drugs easily cross the blood-brain barrier which is one of the most serious problems in the chemotherapy of brain tumors. The outcome of brain tumors treated by chemotherapy, however, is still poor. Although many causes for this unsatisfactory result have been proposed by investigators, 1' 4' j2"13' 16 the emergence of resistance to chloroethylnitrosoureas has become one of the controversial issues, along with the problem of drug resistance in other malignant tumors. 5"6"~9-2z Most recurrent malignant tumors are clinically refractory to the previously employed chemotherapeutic agentsJ 4 Studies on the mechanisms of drug resistance in malignant tumors and leukemia have been reported. 7'8' '7 In spite of the importance of resistance in the chemotherapy of brain tumors, including meningeal gliomatosis, views are divided on this matter. 5'6'9'~'2~ In addition, most of the drug-resistant cell lines have been developed in vitro, and experimental approaches on the behavior of tumor cell population in vivo in the course of treatment with drugs are scarce.
The selection of resistant cells in vivo during treatment seems to be closer to the clinical situation than that in vitro. '8'~9"2''22 In order to investigate the mechanism of resistance against ACNU (1-4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride) in brain tumors and the systematic treatment of ACNU resistance, two ACNU-resistant sublines (C6/ACNU and 9L/ACNU) were isolated and established from rat C6 and 9L brain tumors in vivo and are reported here.
Materials and Methods

Animals and Tumor Tissues
Male Wistar and Fischer 344 rats, each weighing approximately 100 gm, were used in the experiments. The Wistar rats carried the C6 glioma cell line 3 and its ACNU-resistant sublines, while the Fischer 344 rats carried the 9L gliosarcoma cell line 2 and its ACNU-resistant sublines. The C6 rat glioma and 9L rat gliosarcoma are well established.*
Meningeal Gliomatosis Model
Details regarding the present models have been described previously. ~9 Briefly, 0.1 ml of 1 • 107 C6 or 9L brain tumor cells was transplanted percutaneously via a No. 27 needle into the cisterna magna of Wistar or Fischer 344 rats, respectively, under ether anesthesia. These rats are referred to in the present study as "meningeal gliomatosis" rats.
Development of ACNU-Resistant Sublines
The ACNU-resistant sublines of C6 and 9L cell lines were produced by the following procedure. The meningeal gliomatosis rats were treated with a single intrathecal administration of ACNU (l mg/kg) 1 day after tumor implantation. The regimen of the treatment of meningeal gliomatosis rats was determined based on the results of our previous studies. , 8.2, .22 Approximately 14 days after tumor inoculation, the meningeal gliomatosis rats were sacrificed, and the tumors were aseptically removed and disaggregated to single cells 30 minutes after processing in an enzyme cocktail of 0.2% type I collagenase and 0.25% trypsin.t Cells that survived treatment with ACNU were serially transferred to new rats (one group consisting of 10 rats), each receiving the same drug treatment and being sacrificed in order to obtain the tumor cells in the same manner as above. Cells obtained from the C6 and 9L meningeal gliomatosis rats after five successive transplant generations with ACNU treatment were designated as C6/ ACNU and 9L/ACNU cells, respectively. Cells obtained from C6 and 9L meningeal gliomatosis rats after only one transplant generation with ACNU treatment were designated as C6/ACNU1 and 9L/ACNU 1 cells, respectively.
Growth Inhibition Assay In Vitro
Parent (C6 and 9L) and ACNU-resistant (C6/ACNU, 9L/ACNU, C6/ACNU1, and 9L/ACNU1) cells were harvested from each tumor-bearing meningeal gliomatosis rat. The cells were cultured and maintained in Falcon culture bottles containing Eagle's minimum essential medium supplemented with 10% fetal bovine serum, penicillin (50 U/ml), and streptomycin (50 ug/ ml) at 37"C in a humidified atmosphere supplied with 5% COz.~ Except as otherwise indicated, cells were subcultured five times in vitro after being removed * The C6 rat glioma and 9L rat gliosarcoma cell lines were kindly provided by Dr. We used the same methods for analysis of cross resistance to BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea), CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea), methyl CCNU, vincristine, vinblastine, Adriamycin (doxorubicin), ara-C (beta-D-arabinosyl-cytosine), bleomycin, methotrexate, cis-platinum, and 5-fluorouracil.
Measurement of Drug Sensitivity In Vivo
One-tenth of the diluted culture medium containing 1 x 107 parent or ACNU-resistant brain tumor cells was transplanted into the cisterna magna of the rats to produce the meningeal gliomatosis models. The drugs were dissolved (ACNU in 0.9% NaC1 solution and BCNU in 10% aqueous ethanol and 0.9% NaC1 solution) and administered intrathecally at a constant rate of 0.1 ml/100 gm body weight 3 days after tumor inoculation at a dose of 1 mg/kg based on the results of our previous study. , 8.22 Control rats received injections of equal volumes of drug-free diluent. The percentage increase in life span (%ILS) was calculated from the median survival time (MST) as follows:
Ten rats were used for each experimental group. Except as otherwise indicated, after being harvested from the meningeal gliomatosis rats, the tumor cells were subcultured five times in vitro to provide a drug-free environment for the resistant cells. In order to investigate the stability of the acquired resistance during the serial passages in vivo under drug-free pressure, the drug sensitivity of C6/ACNU and 9L/ACNU cells was compared between the first and fifth transplant generations after ACNU treatment was discontinued. At the same time, ACNU-resistant (C6/ACNU, 9L/ACNU, C6/ ACNU 1, and 9L/ACNU 1) cell-bearing rats were treated intrathecally with ACNU (i mg/kg) to ascertain the influence of in vitro passages on the stability of the acquired resistance in vivo.
Results
Isolation and Establishment of the ACNU-Resistant Cell Lines
The process of ACNU-resistance development during treatment was demonstrated by changes in the life span of 10 ACNU-treated meningeal gliomatosis rats in each transplant generation. With successive transplantation with ACNU, C6 and 9L brain tumor cells acquired complete resistance against ACNU at the second transplant generation (Fig. 1) , although the decrease in sensitivity of C6 cells to ACNU was not remarkable due to the low sensitivity of the original C6 glioma cells against ACNU. In the ACNU-resistant meningeal gliomatosis rat models produced by intracisternal inoculation of C6/ACNU or 9L/ACNU ceils, the %ILS was not statistically prolonged by treatment with ACNU compared with that of the controls (Table 1) . Population doubling times for C6, C6/ACNU, 9L, and 9L/ACNU cells were 20.15, 22.32, 21.85, and 22.96 hours, respectively, and plating efficiencies were 83.6%, 81.2%, 79.8%, and 78.5%, respectively. The resistant sublines did not statistically differ in these parameters from the parent cells. Both ACNU-resistant cell lines were morphologically indistinguishable from the parent cell lines. in the first transptant generation was 39.4%, 4.1%, 112.0%, and 7.8%, respectively, and in the fifth transplant generation was 40.3%, 2.0%, 102.9%, and 3.2%, respectively. The difference in %ILS between the first and fifth transplant generations was not statistically significant. These data demonstrate that both resistant sublines were quite stable, even after five transplant generations in vivo (about 75 days) under no selection pressure.
Stability of the Acquired Resistance
The sensitivity of ACNU-resistant (C6/ACNU 1, C6/ ACNU, 9L/ACNUI, and 9L/ACNU) and parent (C6 and 9L) cells to ACNU after five passages in vitro is illustrated in Fig. 2 . The mean ICs0 of ACNU for C6, C6/ACNU, and C6/ACNU1 cells after subculture five times was 26.8, 383, and 1 19 uM, respectively, and that for 9L, 9L/ACNU, and 9L/ACNU1 cells was 2.85, 210.2, and 98.2 uM, respectively. The mean ICs0 of ACNU for C6/ACNU, C6/ACNUI, 9L/ACNU, and 9L/ACNU1 cells before subculture was 388, 379,213.5, and 211.5 #M, respectively. These results indicate that the cells from the first transplant generation (C6/ ACNUI and 9L/ACNUI) lose resistance during serial passages and are less resistant than those that have received five cycles of drug treatment (C6/ACNU and 9L/ACNU). At the same time, the sensitivity of C6/ ACNU1 and 9L/ACNUI cells was higher than that of C6/ACNU and 9L/ACNU cells in in vivo experiments using the meningeal gliomatosis rat models (Tables 1  and 2 ). These data indicate the decrease in ACNU resistance in the incompletely resistant cells during serial passages in vitro under no selection pressure.
Cross Resistance to Other Chemotherapeutic Agents
From the results of cross-resistance to other nitrosoureas, such as BCNU, CCNU, and methyl CCNU, a correlated pattern of cross-resistance to the chloroethylnitrosoureas was observed in both C6/ACNU and 9L/ACNU cell lines (Table 3 ). In addition to remarkable cross-resistance to the chloroethylnitrosoureas, these cell lines also exhibited remarkable resistance to vincristine, vinblastine, Adriamycin, and ara-C, but not to bleomycin, methotrexate, cis-platinum, and 5-fluorouracil (Table 4) .
Discussion
Two ACNU-resistant sublines derived from rat C6 and 9L brain tumor cells were isolated and established T. K. Yoshida, et al. in vivo during the treatment of meningeal gliomatosis rat models with ACNU in this report. Although there have been many studies of the mechanisms of drug resistance and patterns of cross-resistance TM 1.14,17.20-22 of tumor cells, most of these were based on in vitro observations. In this study, emphasis was placed on the observation of drug resistance development in the course of therapy with ACNU in vivo in a meningeal gliomatosis rat modelJ 9 The emergence of ACNUresistant cells during chemotherapy of patients with malignant brain tumors and meningeal gliomatosis has become one of the most significant problems. ~9' 2~ Since intrathecal administration of ACNU has been advocated as a new therapeutic modality for patients with leptomeningeal tumors, including meningeal gliomatosis, ~0.~8 a study that selects the resistant cells by treating meningeal gliomatosis models with intrathecal ACNU administration seems to reflect more closely the clinical situation.
Occurrence of Resistance
Occurrence of resistance to ACNU was unexpectedly rapid after intrathecal treatment of meningeal gliomatosis rat models with ACNU. The resistant brain tumor cells obtained from C6 and 9I. meningeal gliomatosis rats demonstrated complete resistance to ACNU in vivo at the second transplant generation. However, these ACNU-resistant (C6/ACNU 1 and 9L/ACNU 1) cells exhibited a decrease in resistance during the serial passages in vitro and in vivo. This implies that the selective pressure after a single treatment with ACNU was not enough to allow the resistant cells to outgrow completely the sensitive tumor cell population while the incomplete resistance was presented in these resistant cell lines. On the other hand, complete ACNU resistance had been acquired at the fifth transplant generation and remained stable both in vitro and in vivo for approximately 7 5 days in the absence of ACNU.
Basis of Resistance
It is still undetermined whether the drug-resistant sublines are established by mutation and selection by antitumor agents or from simple selection of resistant clones pre-existing in the original population. Stability of the acquired resistance for over 2 months was proven in this investigation. Furthermore, the same cell lines have exhibited stability of resistance under drug-free conditions for over I year after the establishment of ACNU resistance (data not shown), which does not necessarily mean that this acquired resistance will be stable thereafter. If this phenotype of drug resistance was acquired by physiological adaptation, it would be lost at least partially in this period of passages in a drugfree environment. It might therefore be possible that this change in drug sensitivity is related to genetic mutation. Indeed, Kokunai, et al., 9 have recently studied the karyotype of ACNU-resistant 9L glioma cells and observed the chromosomal aberrations in the resistant cells. In relation to clinical chemotherapy of malignant tumors, it is important that antitumor agents such as ACNU caused resistance from originally sensitive C6 and 91. brain tumor cells in vivo. This is likely to be consistent with clinical observations in which the tumor cells often become resistant to initially effective chemotherapeutic agents.~2-'4'~'~9"22
Mechanisms of Resistance
The various mechanisms of resistance to nitrosoureas in glioma cells, which mainly include a capability of deoxyribonucleic acid (DNA) repair 5,6'9:' and a different uptake and release at the cell membrane, 2~ have been previously described. The analysis of cross-resistance to different drugs with dissimilar chemical structures and mechanisms of action might provide clues for explaining mechanisms of drug resistance. In the present study, ACNU-resistant sublines from C6 and 9L brain tumor cells displayed cross-resistance to three other chloroethylnitrosoureas, namely BCNU, CCNU, and methyl CCNU. These agents are regarded as bifunctional alkylating agents, of which the main cytocidal action is believed to be DNA interstrand crosslinking, s'6 In the study of cross-resistance, Kokunai, et at., 9 reported a complete cross-resistance of ACNUresistant 9L cells, subcloned in vitro, to the same three chloroethylnitrosoureas as above and to three more alkylating agents, nitrogen mustard, cyclophosphamide, and cis-platinum. They also suggested from the results of their cross-resistance study that the mechanism of nitrosourea-resistance may be alteration in the repair system of DNA interstrand cross-linking, which other investigators have also reported. 56'~' Therefore, increased DNA repair may be responsible for the resistance of ACNU-resistant 9L sublines to chloroethylnitrosoureas. However, this is unlikely to be the total explanation.
In contrast to these studies, we found collateral sensitivity to cis-platinum (an alkylating agent) and a complete resistance to vincristine, Adriamycin, vinblastine, and ara-C. The basis for the observed cross-resistance is, at the present time, unknown. This type of pleiotropic cross-resistance is associated with membrane alterations, although only impairment of catabolic activity of the salvage pathway has been reported in regard to ara-C resistance. 7,8,~7 Indeed, we have shown the decreased uptake and increased efflux of ACNU in the same cell lines used in this experiment. 2~
The discrepancy between the results reported by Kokunai, et al.,9 and our study raises a number of intriguing questions regarding the mechanism of ACNU resistance. Although the same cell line, 9L brain tumor, was used in both experiments, the data of cross-resistance were in part inconsistent. This is probably because their resistant lines were established in vitro and, furthermore, cell lines isolated even from the same original celt line exhibit a heterogeneity in drug sensitivity) 3 Hence, multifactorial mechanisms responsible for ACNU resistance in brain tumors should be considered. We are currently investigating the exact basis of ACNU resistance with these brain tumor cell lines. The study of drug resistance in vivo and with cell lines established in vivo should allow us to further understand the mechanism of ACNU resistance.
